Inhibikase Therapeutics is advancing its lead candidate, IKT-001, into a globally adaptive pivotal Phase 3 trial targeting Pulmonary Arterial Hypertension, emphasizing endpoints such as pulmonary vascular resistance and six-minute walk distance. This clinical momentum coincides with a significant increase in operating losses, which reached $51.97 million in FY2025, up sharply from prior years. The company’s robust liquidity position, bolstered by a $93.6 million capital raise in late 2025, supports ongoing development but underscores the need for sustained funding until potential regulatory approval. Board-level governance initiatives include focused cybersecurity oversight to safeguard critical data integrity throughout the trial process.